|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||193.51 - 199.10|
|52-week range||193.51 - 199.10|
|Beta (5Y monthly)||0.80|
|PE ratio (TTM)||N/A|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
CAMBRIDGE, Mass., September 30, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from exploratory endpoints and additional analyses of prespecified patient subgroups for the primary and secondary endpoints in the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The results were presented during a moderated pos
Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.
The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.